| Literature DB >> 27022627 |
Lily M Y Yu1, Denis Polygalov1, Marie E Wintzer1, Ming-Ching Chiang1, Thomas J McHugh1.
Abstract
Epilepsy is a neurological disorder defined by the presence of seizure activity, manifest both behaviorally and as abnormal activity in neuronal networks. An established model to study the disorder in rodents is the systemic injection of kainic acid, an excitatory neurotoxin that at low doses quickly induces behavioral and electrophysiological seizures. Although the CA3 region of the hippocampus has been suggested to be crucial for kainic acid-induced seizure, because of its strong expression of kainate glutamate receptors and its high degree of recurrent connectivity, the precise role of excitatory transmission in CA3 in the generation of seizure and the accompanying increase in neuronal oscillations remains largely untested. Here we use transgenic mice in which CA3 pyramidal cell synaptic transmission can be inducibly silenced in the adult to demonstrate CA3 excitatory output is required for both the generation of epileptiform oscillatory activity and the progression of behavioral seizures.Entities:
Keywords: CA3; gamma; hippocampus; kainic acid; seizure; tetanus toxin
Mesh:
Substances:
Year: 2016 PMID: 27022627 PMCID: PMC4797997 DOI: 10.1523/ENEURO.0003-16.2016
Source DB: PubMed Journal: eNeuro ISSN: 2373-2822
Statistical table
| Data structure | Type of test | Observed power (α=0.05) | |
|---|---|---|---|
| Normally distributed | Two-way repeated-measure ANOVA | <0.0001 | |
| Bonferroni multiple comparisons (CA3-TeTX × control) | |||
| 0 | >0.05 | ||
| 10 | >0.05 | ||
| 20 | >0.05 | ||
| 30 | <0.01 | ||
| 40 | <0.0001 | ||
| 50 | <0.001 | ||
| 60 | <0.0001 | ||
| 70 | <0.0001 | ||
| 80 | <0.0001 | ||
| 90 | <0.0001 | ||
| 100 | <0.0001 | ||
| 110 | <0.0001 | ||
| 120 | <0.0001 | ||
| Normally distributed | Unpaired | <0.0001 | |
| Normally distributed | Welch | 0.0002 | |
| Normally distributed | Two-way ANOVA (genotype × drug) | 0.003 | |
| Bonferroni multiple comparisons (KA vs saline) | |||
| KA | <0.0001 | ||
| Saline | >0.05 | ||
| Normally distributed | Two-way ANOVA (genotype × drug) | 0.0011 | |
| Bonferroni multiple comparisons (KA vs saline) | |||
| KA | <0.001 | ||
| Saline | >0.05 | ||
| Normally distributed | Two-way ANOVA (genotype × drug) | 0.0757 | |
| Two-way repeated-measure ANOVA (genotype) | 0.6035 | ||
| Two-way repeated-measure ANOVA (drug) | <0.0001 | ||
| Bonferroni multiple comparisons (KA vs saline) | |||
| KA | >0.05 | ||
| Saline | >0.05 | ||
| Normally distributed | Two-way repeated-measure ANOVA (time × control group) | ||
| Theta (time × group) | 0.9996 | ||
| Theta (time) | <0.0001 | ||
| Theta (group) | 0.8227 | ||
| Low gamma (time × group) | 0.7955 | ||
| Low gamma (time) | <0.0001 | ||
| Low gamma (group) | 0.405 | ||
| High gamma (time × group) | 0.9379 | ||
| High gamma (time) | <0.0001 | ||
| High gamma (group) | 0.3334 | ||
| Normally distributed | Two-way repeated-measure ANOVA (time × group) theta band | <0.0001 | |
| Bonferroni multiple comparisons (CA3-TeTX × control ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (CA3-TeTX × control OFF DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (CA3-TeTX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control ON DOX × control OFF DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control ON DOX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control OFF DOX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Normally distributed | Two-way repeated-measure ANOVA (time × group) low gamma band | <0.0001 | |
| Bonferroni multiple comparisons (CA3-TeTX × control ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (CA3-TeTX × control OFF DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (CA3-TeTX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control ON DOX × control OFF DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control ON DOX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control OFF DOX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Normally distributed | Two-way repeated-measure ANOVA (time × group) high gamma band | <0.0001 | |
| Bonferroni multiple comparisons (CA3-TeTX × control ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (CA3-TeTX × control OFF DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (CA3-TeTX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control ON DOX × control OFF DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control ON DOX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Bonferroni multiple comparisons (control OFF DOX × CA3-TeTX ON DOX) | |||
| −20 | |||
| −15 | |||
| −10 | |||
| −5 | |||
| 0 | |||
| 5 | |||
| 10 | |||
| 15 | |||
| 20 | |||
| 25 | |||
| 30 | |||
| 35 | |||
| 40 | |||
| 45 | |||
| 50 | |||
| 55 | |||
| 60 | |||
| 65 | |||
| 70 | |||
| 75 | |||
| 80 | |||
| 85 | |||
| 90 | |||
| 95 | |||
| 100 | |||
| 105 | |||
| Normally distributed | Two-way repeated-measure ANOVA (time × group) | <0.0001 | |
| Bonferroni multiple comparisons (CA3-TeTX × control) | |||
| −20 | >0.05 | ||
| −15 | >0.05 | ||
| −10 | >0.05 | ||
| −5 | >0.05 | ||
| 0 | >0.05 | ||
| 5 | >0.05 | ||
| 10 | >0.05 | ||
| 15 | >0.05 | ||
| 20 | >0.05 | ||
| 25 | >0.05 | ||
| 30 | >0.05 | ||
| 35 | <0.05 | ||
| 40 | <0.01 | ||
| 45 | <0.0001 | ||
| 50 | <0.0001 | ||
| 55 | <0.0001 | ||
| 60 | <0.0001 | ||
| 65 | <0.0001 | ||
| 70 | <0.0001 | ||
| 75 | <0.0001 | ||
| 80 | <0.0001 | ||
| 85 | <0.0001 | ||
| 90 | <0.0001 | ||
| 95 | <0.0001 | ||
| 100 | <0.0001 | ||
| 105 | <0.0001 | ||
| Normally distributed | Two-way repeated-measure ANOVA (time × group) | <0.0001 | |
| Bonferroni multiple comparisons (CA3-TeTX × control) | |||
| −20 | >0.05 | ||
| −15 | >0.05 | ||
| −10 | >0.05 | ||
| −5 | >0.05 | ||
| 0 | >0.05 | ||
| 5 | >0.05 | ||
| 10 | >0.05 | ||
| 15 | >0.05 | ||
| 20 | <0.05 | ||
| 25 | <0.01 | ||
| 30 | <0.0001 | ||
| 35 | <0.0001 | ||
| 40 | <0.0001 | ||
| 45 | <0.0001 | ||
| 50 | <0.0001 | ||
| 55 | <0.0001 | ||
| 60 | <0.0001 | ||
| 65 | <0.0001 | ||
| 70 | <0.0001 | ||
| 75 | <0.0001 | ||
| 80 | <0.0001 | ||
| 85 | <0.001 | ||
| Normally distributed | Two-way repeated-measure ANOVA (time × group) | <0.0001 | |
| Bonferroni multiple comparisons (CA3-TeTX × control) | |||
| −20 | >0.05 | ||
| −15 | >0.05 | ||
| −10 | >0.05 | ||
| −5 | >0.05 | ||
| 0 | >0.05 | ||
| 5 | >0.05 | ||
| 10 | >0.05 | ||
| 15 | >0.05 | ||
| 20 | >0.05 | ||
| 25 | <0.05 | ||
| 30 | <0.01 | ||
| 35 | <0.001 | ||
| 40 | <0.0001 | ||
| 45 | <0.0001 | ||
| 50 | <0.0001 | ||
| 55 | <0.0001 | ||
| 60 | <0.001 | ||
| 65 | <0.001 | ||
| 70 | <0.01 | ||
| 75 | <0.01 | ||
| 80 | <0.01 | ||
| 85 | <0.01 | ||
| 90 | <0.01 | ||
| 95 | <0.01 | ||
| 100 | <0.01 | ||
| 105 | <0.05 |
Figure 1.Genetic blockade of CA3 synaptic transmission attenuates acute KA-induced seizures. , The mean behavioral seizure score following kainic acid injection was significantly reduced in CA3-TeTX mice. Analysis revealed that () the fraction of CA3-TeTX mice reaching stage 3 seizures (forelimb clonus and rearing) was reduced compared with control mice. The mutant mice also had () a significantly lower maximal seizure score and () a lower cumulative seizure score than control mice. ****p<0.0001, ***p<0.001, **p<0.01. Control, n=9; CA3-TeTX n=9.
Figure 2.Loss of CA3 output causes a decrease in , Examples of c-fos protein expression in the dorsal hippocampus of control (top) and CA3-TeTX (bottom) mice 2.5 h after injection with kainic acid (left) or saline (right). Quantification of the fluorescent c-fos expression signal finds significantly higher signal in the () CA1 and () CA3 regions of the control mice injected with KA compared with the CA3-TeTX/KA and both saline groups. However, in the () DG, robust c-fos expression was evident in both genotypes following KA injection. ***p<0.001. Control + KA, n=7; control + saline, n=6; CA3-TeTX + KA, n=8; CA3-TeTX + saline, n=4.
Figure 3.Loss of CA3 output prevents increases in CA1 oscillations induced by KA. , Example LFP recordings in CA1 stratum radiatum from a control (blue; top) and CA3-TeTX (red; bottom) mouse 60 min after kainic acid injection. For each genotype the top panel shows the raw LFP, the second panel the theta band filtered LFP, the third the slow gamma filtered LFP, and the bottom the fast gamma filtered LFP. Note the scale in the control traces is 10× that of the CA3-TeTX mice. KA injection lead to a significant increase in power in the () theta band and the () slow gamma band 35 min postinjection, and in the () fast gamma band 25 min following KA. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. Control, n=22 (control ON DOX, n=12; control OFF DOX, n=4; CA3-TeTX ON DOX, n=6); CA3-TeTX, n=16.